Effects Of Diet-induced Weight Loss With Or Without Moderate Aerobic Exercise On Skeletal Muscle Mass In Overweight Older Adults.

2008 ◽  
Vol 40 (Supplement) ◽  
pp. S75
Author(s):  
Peter J. Chomentowski ◽  
John Dube ◽  
Francesca Amati ◽  
Bret H. Goodpaster
Obesity ◽  
2018 ◽  
Vol 26 (8) ◽  
pp. 1255-1260 ◽  
Author(s):  
Gary R. Hunter ◽  
David R. Bryan ◽  
Juliano H. Borges ◽  
M. David Diggs ◽  
Stephen J. Carter

2015 ◽  
Vol 7 (3) ◽  
pp. 312-321 ◽  
Author(s):  
Stefanos Tyrovolas ◽  
Ai Koyanagi ◽  
Beatriz Olaya ◽  
Jose Luis Ayuso-Mateos ◽  
Marta Miret ◽  
...  

2017 ◽  
Vol 135 (5) ◽  
pp. 434-443 ◽  
Author(s):  
Ricardo Aurélio Carvalho Sampaio ◽  
Priscila Yukari Sewo Sampaio ◽  
Luz Albany Arcila Castaño ◽  
João Francisco Barbieri ◽  
Hélio José Coelho Júnior ◽  
...  

2020 ◽  
Author(s):  
Lazuardhi Dwipa ◽  
Rini Widiastuti ◽  
Alif Bagus Rakhimullah ◽  
Marcellinus Maharsidi ◽  
Yuni Susanti Pratiwi ◽  
...  

Abstract Background The relationship between obesity and low bone mineral density (BMD) in older adults is still unclear. Most of the previous study did not account the factor of sarcopenia which is the progressive loss of skeletal muscle mass due to aging, and distribution of fat in obesity. Thus, this study was aimed to explore the correlation between appendicular skeletal muscle mass (ASMM), total fat mass (FM), and truncal fat mass (TrFM) as well as indexes (ASMM/FM and ASMM/TrFM ratio) with BMD in older adults.Methods This was an analytic cross-sectional study. Dual x-ray absorptiometry (DXA) and bioelectric impedance analysis (BIA) were used to assess BMD and body composition, respectively. Appendicular Skeletal Muscle Mass (ASMM) were used in the analysis to reflect sarcopenia, Fat Mass (FM) and Trunkal Fat Mass (TrFM) were used to reflect general and central obesity, respectively. All data were obtained from medical records of Geriatric Clinic of Hasan Sadikin General Hospital Bandung Indonesia from January 2014 to December 2018. The correlation between body compositions variable with BMD were analyzed using Spearman’s test. We also conducted a comparison analysis of body composition variables between low and normal BMD using Mann-Whitney test. Results A total of 112 subjects were enrolled in the study. ASMM and TrFM were positive (rs=0.517, p<0.001) and negative (rS=-0.22, p=0.02) correlated with BMD, respectively. FM were not correlated with BMD, rS=-0.113 (p=0.234). As indexes, ASMM/FM and ASMM/TrFM had positive correlation with BMD, rS=0.277 (p<0.001), and rS=0.391 (p<0.001), respectively. The ASMM, TrFM, and ASMM/TrFM ratio between normal and low BMD also significantly different (p<0.001), meanwhile FM were not (p=0.204).Conclusion ASMM and TrFM have a positive and negative correlation with BMD, respectively. ASMM/TrFM ratio as new sarcopenia-central obesity index has a positive correlation with BMD.


2020 ◽  
Vol 7 (1) ◽  
pp. e000551 ◽  
Author(s):  
Siao Nge Hoon ◽  
Katrina Fyfe ◽  
Carolyn J Peddle-McIntyre ◽  
Samantha Bowyer ◽  
Felicity Hawkins ◽  
...  

IntroductionCachexia is common in malignant mesothelioma (MM); half of patients have malnutrition and low skeletal muscle mass. Malnourished patients have worse quality of life (QoL). Weight loss is strongly associated with poor survival. Anamorelin is an oral ghrelin receptor agonist that improves appetite, body weight and QoL in advanced cancer. The aim of this study is to examine the efficacy of anamorelin in improving appendicular skeletal muscle mass (ASM) and patient-reported outcomes in patients with MM with cachexia.Methods and analysisA single-centre, phase II, randomised, placebo-controlled cross-over pilot study with 28-day treatment periods and 3-day washout. Forty patients will be randomised. Primary outcome is change in ASM relative to height measured by dual energy X-ray absorptiometry at end of period 1. Secondary outcomes include cancer-specific and cachexia-related QoL, objective physical activity, dietary intake and adverse events. Eligible patients will have confirmed MM, Eastern Cooperative Oncology Group 0–2, expected survival >3 months and cachexia (defined as >5% weight loss in 6 months or body mass index <20 kg/m2 with weight loss >2%).Ethics and disseminationEthical approval has been granted. Results will be reported in peer-reviewed publications.Trial registration numberAustralian New Zealand Clinical Trials Registry (U1111-1240-6828).


Obesity ◽  
2013 ◽  
Vol 21 (7) ◽  
pp. 1350-1356 ◽  
Author(s):  
A.S. Ryan ◽  
G. Li ◽  
J.B. Blumenthal ◽  
H.K. Ortmeyer

Sign in / Sign up

Export Citation Format

Share Document